Informations générales (source: ClinicalTrials.gov)
A Phase II, Open-label, Platform Study, to Evaluate Immunotherapy-based Combinations in Participants With Advanced Non-Small Cell Lung Cancer
Interventional
Phase 2
Gilead Sciences (Voir sur ClinicalTrials)
février 2023
décembre 2027
08 mai 2026
The purpose of this study is to assess the objective response rate (ORR) of
immunotherapy-based combination therapy and to assess the safety and tolerability of
immunotherapy-based combination therapy.
Etablissements
| Les établissements d'Île-de-France ayant mis à jour leurs données Origine et niveau de fiabilité des données | |||||
|---|---|---|---|---|---|
| HOPITAL FOCH | Jaafar BENNOUNA | 11/05/2026 07:26:27 | Contacter | ||
| Les établissements sans correspondance certaine dans le répertoire FINESS dont les données sont issues de ClinicalTrials.gov Origine et niveau de fiabilité des données | |||||
| CHU Bordeaux Centre Francois Magendie Hôpital du Haut Lévèque - 33604 - Bordeaux - France | Contact (sur clinicalTrials) | ||||
| Hopital FOCH - Suresnes - France | Contact (sur clinicalTrials) | ||||
| Hospices Civils de Lyon Centre Hospitalier Lyon Sud - 69495 - Lyon - France | Contact (sur clinicalTrials) | ||||
| Institut De Cancerologie Strasbourg Europe ICANS - 67033 - Strasboug - France | Contact (sur clinicalTrials) | ||||
Critères
Tous
- Histologically or cytologically documented Stage IV metastatic, NSCLC
- Eastern Cooperative Oncology Group performance status (ECOG PS) of 0 to 1
- At least one measurable target lesion per RECIST v1.1.
- Adequate organ function
- Participants must be willing to provide adequate tumor tissue
Exclusion Criteria:
- Underlying medical conditions that, in the Investigator's or Sponsor's opinion, will
make the administration of Investigational Product(s) (IPs) hazardous
- Use of any live vaccines against infectious diseases within 28 days of first dose of
IP(s).
- Use of supra-physiologic doses of corticosteroids (> 10 mg/day of oral prednisone or
equivalent) or immunosuppressive medications ≤ 14 days before the initiation of
study treatment (absorbable topical corticosteroids are not excluded).
- Has known psychiatric or substance abuse disorders that would interfere with
cooperation with the requirements of the trial.
- Any active autoimmune disease or a documented history of autoimmune disease or
syndrome that required systemic treatment in the past 2 years (ie, with use of
disease-modifying agents, corticosteroids, or immunosuppressive drugs), except for
vitiligo or resolved childhood asthma/atopy
NOTE: Other protocol defined Inclusion/Exclusion criteria may apply.